N@N

Market Maker Surveillance Report. FXI, VWO, SPY, VITA, LBTYA, MRNA, Bearishly Biased Price Friction For Tuesday, May 17th 2011

^{Published on 2011-05-17 17:50:33 - WOPRAI}
 

May 17, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2783 companies with "abnormal" market making, 1854 companies with positive Friction Factors and 2958 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. ISHARES FTSE CHINA 25 INDEX (NYSE:FXI), VANGUARD MSCI EMERGING MARKE (NYSE:VWO), SPDR S&P 500 ETF TRUST (NYSE:SPY), ORTHOVITA INC (NASDAQ:VITA), LIBERTY GLOBAL INC-A (NASDAQ:LBTYA), MARINA BIOTECH INC (NASDAQ:MRNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     FXI        $-0.020      -0.05%       11,088,740      46.00%       3,021,710       12.53%       8,067,030       Abnormal
     VWO        $-0.110      -0.23%       7,294,916       33.49%       4,955,798       22.75%       2,339,118       Abnormal
     SPY        $-0.120      -0.09%       47,831,200      25.25%       41,756,365      22.04%       6,074,835       Abnormal
     VITA       $-0.010      -0.26%       5,979,754       58.60%       4,224,653       41.40%       1,755,101       Abnormal
     LBTYA      $-0.770      -1.69%       3,773,667       48.82%       2,077,203       26.87%       1,696,464       Abnormal
     MRNA       $-0.150      -38.46%      9,360,364       64.59%       5,131,524       35.41%       4,228,840       Abnormal

For example, the chart above shows FXI with 8,067,030 greater shares of buying than selling (NetVol) and the stock price was down $-0.02000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

ISHARES FTSE CHINA 25 INDEX (NYSE:FXI) - ISHARES TR FTSE I

VANGUARD MSCI EMERGING MARKE (NYSE:VWO) - VANGRD EMRG MKT V

SPDR S&P 500 ETF TRUST (NYSE:SPY) - S&P DEP RECEIPTS

ORTHOVITA INC (NASDAQ:VITA) - Orthovita, Inc., a specialty spine and orthopedic company, develops and markets orthobiologic and biosurgery products. The companys orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone; and the biosurgery platform provides products for controlling intra-operative bleeding/hemostasis. Its orthobiologic product portfolio comprises Vitoss bone graft substitute, a high-porous resorbable beta-tricalcium phosphate bone graft substitute used to help the body guide the three-dimensional regeneration of the patients own bone; Bone Marrow Aspiration System with imbibe needles, syringes, and imbibe disposable delivery instrumentation, which provides spine and orthopedic surgeons with a method for harvesting a patients own bone marrow; Cortoss Bone Augmentation Material, a polymer composite for use in various surgical procedures to provide structural stability and reinforcement of the bones after surgery; and Aliquot Delivery System that facilitates delivery of materials to bony sites, including delivery of Cortoss product directly to the surgical site. The companys biosugery products include Vitagel surgical hemostat, a composite liquid hemostat that combines the biomaterials bovine thrombin and bovine collagen with the patients autologous plasma, and applied in the spine, hip, and knee replacement surgeries; and Vitasure Absorbable Hemostat, a plant-based hemostat product that can be deployed throughout surgery. It sells its products in the United States and internationally through a network of direct sales representatives and independent non-stocking distributors. The company has strategic partnerships with Kensey Nash Corporation; Angiotech Pharmaceuticals (U.S.), Inc.; and Medafor, Inc. Orthovita was founded in 1992 and is headquartered in Malvern, Pennsylvania.

LIBERTY GLOBAL INC-A (NASDAQ:LBTYA) - Liberty Global, Inc. provides video, voice, and broadband Internet services primarily in Europe, Japan, and Chile. The company offers various broadband distribution services over its cable television systems, including video, broadband Internet, and telephony. It also provides video services through direct-to-home satellite or multi channel multipoint distribution systems; analog video services consisting of basic programming and expanded basic programming; digital video services comprising basic programming and premium services, as well as pay-per-view programming, including video-on-demand and near-video-on-demand, digital video recorders, and high definition television services; and broadband Internet services. In addition, Liberty Global provides telephony services that include circuit switched telephony services and voice-over-Internet-protocol (VoIP) telephony services, as well as offers mobile telephony services using third party networks. Further, it owns programming networks that provide video programming channels to multi channel distribution systems owned by the company, as well as owned by third parties. As of December 31, 2008, Liberty Global owned and operated networks that passed approximately 34,782,600 homes; and served approximately 15,190,300 video subscribers and 6,727,600 broadband Internet subscribers, as well as 5,230,100 telephony subscribers. The company was founded in 2004 and is based in Englewood, Colorado.

MARINA BIOTECH INC (NASDAQ:MRNA) - Marina Biotech, Inc. operates as a biotechnology company that focuses on the development and commercialization of therapeutic products based on RNA interference (RNAi). Its pipeline includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome); and two preclinical programs in hepatocellular carcinoma and bladder cancer. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is headquartered in Bothell, Washington.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net